Kinnate Biopharma Price on February 14, 2023

KNTEDelisted Stock  USD 2.96  0.27  8.36%   
If you're considering investing in Kinnate Stock, it is important to understand the factors that can impact its price. As of today, the current price of Kinnate Biopharma stands at 2.96, as last reported on the 29th of December, with the highest price reaching 3.25 and the lowest price hitting 2.95 during the day. We have found twenty-three technical indicators for Kinnate Biopharma, which you can use to evaluate the volatility of the firm. Please verify Kinnate Biopharma's Standard Deviation of 5.59, risk adjusted performance of 0.0044, and Mean Deviation of 4.52 to check out if the risk estimate we provide is consistent with the expected return of 0.0%.
  
Kinnate Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
KNTE
Based on monthly moving average Kinnate Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kinnate Biopharma by adding Kinnate Biopharma to a well-diversified portfolio.

Related Headline

ACELYRIN, INC Headline on 4th of May 2023

Filed transaction by Acelyrin Inc director. Unconventional Insider trading

Kinnate Biopharma Valuation on February 14, 2023

It is possible to determine the worth of Kinnate Biopharma on a given historical date. On February 14, 2023 Kinnate was worth 6.64 at the beginning of the trading date compared to the closed value of 6.65. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Kinnate Biopharma stock. Still, in general, we apply an absolute valuation method to find Kinnate Biopharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kinnate Biopharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Kinnate Biopharma's related companies.
 Open High Low Close Volume
  6.78    6.78    6.42    6.65    67,409  
02/14/2023
  6.64    6.82    6.34    6.65    283,193  
  6.61    6.91    6.60    6.81    53,400  
Backtest Kinnate Biopharma  |  Kinnate Biopharma History  |  Kinnate Biopharma Valuation   PreviousNext  
Open Value
6.64
6.65
Closing Value
6.64
Upside

Kinnate Biopharma Trading Date Momentum on February 14, 2023

On February 15 2023 Kinnate Biopharma was traded for  6.81  at the closing time. The top price for the day was 6.91  and the lowest listed price was  6.60 . The trading volume for the day was 53.4 K. The trading history from February 15, 2023 was a factor to the next trading day price growth. The trading delta at closing time against the next closing price was 2.41% . The trading delta at closing time against the current closing price is 10.98% .

Kinnate Biopharma Fundamentals Correlations and Trends

By evaluating Kinnate Biopharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Kinnate Biopharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Kinnate financial account trend analysis is a perfect complement when working with valuation or volatility modules.

About Kinnate Biopharma Stock history

Kinnate Biopharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Kinnate is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Kinnate Biopharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Kinnate Biopharma stock prices may prove useful in developing a viable investing in Kinnate Biopharma
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Kinnate Biopharma Stock Technical Analysis

Kinnate Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Kinnate Biopharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Kinnate Biopharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Price Boundaries

Kinnate Biopharma Period Price Range

Low
December 29, 2024
0.00  NaN%
High

 0.00 

     

 0.00 

Kinnate Biopharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.

Kinnate Biopharma December 29, 2024 Market Strength

Market strength indicators help investors to evaluate how Kinnate Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kinnate Biopharma shares will generate the highest return on investment. By undertsting and applying Kinnate Biopharma stock market strength indicators, traders can identify Kinnate Biopharma entry and exit signals to maximize returns

Kinnate Biopharma Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for Kinnate Biopharma's price direction in advance. Along with the technical and fundamental analysis of Kinnate Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Kinnate to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios